This offers not only the opportunity to generate isogenic control lines by correcting or introducing mutations into the CFTR gene but also to edit potential genomic modifiers of CF disease such as cytokeratin 8, Syntaxin 1A, or ets homologous factor [32–34]. This evidence concerns the gene CFTR and cystic fibrosis.